Journal of Molecular Endocrinology

References

1. ↵
   1. Ahn JD,
   2. Dubern B,
   3. Lubrano-Berthelier C,
   4. Clement K &
   5. Karsenty G

   2006 Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147 3196–3202.doi:10.1210/en.2006-0281.
2. ↵
   1. Allison SJ,
   2. Baldock P,
   3. Sainsbury A,
   4. Enriquez R,
   5. Lee NJ,
   6. Lin EJ,
   7. Klugmann M,
   8. During M,
   9. Eisman JA,
   10. Li M
   11. et al.

   2006 Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. Journal of Biological Chemistry 281 23436–23444.doi:10.1074/jbc.M604839200.
3. ↵
   1. Baldock PA,
   2. Sainsbury A,
   3. Couzens M,
   4. Enriquez RF,
   5. Thomas GP,
   6. Gardiner EM &
   7. Herzog H

   2002 Hypothalamic Y2 receptors regulate bone formation. Journal of Clinical Investigation 109 915–921.doi:10.1172/JCI14588.
4. ↵
   1. Baldock PA,
   2. Sainsbury A,
   3. Allison S,
   4. Lin EJ,
   5. Couzens M,
   6. Boey D,
   7. Enriquez R,
   8. During M,
   9. Herzog H &
   10. Gardiner EM

   2005 Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. Journal of Bone and Mineral Research 20 1851–1857.doi:10.1359/JBMR.050523.
5. ↵
   1. Baldock PA,
   2. Allison S,
   3. McDonald MM,
   4. Sainsbury A,
   5. Enriquez RF,
   6. Little DG,
   7. Eisman JA,
   8. Gardiner EM &
   9. Herzog H

   2006 Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. Journal of Bone and Mineral Research 21 1600–1607.doi:10.1359/jbmr.060705.
6. ↵
   1. Baldock PA,
   2. Allison SJ,
   3. Lundberg P,
   4. Lee NJ,
   5. Slack K,
   6. Lin EJ,
   7. Enriquez RF,
   8. McDonald MM,
   9. Zhang L,
   10. During MJ
   11. et al.

   2007 Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. Journal of Biological Chemistry 282 19092–19102.doi:10.1074/jbc.M700644200.
7. ↵
   1. Baldock PA,
   2. Lee NJ,
   3. Driessler F,
   4. Lin S,
   5. Allison S,
   6. Stehrer B,
   7. Lin EJ,
   8. Zhang L,
   9. Enriquez RF,
   10. Wong IP
   11. et al.

   2009 Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS ONE 4 e8415doi:10.1371/journal.pone.0008415.
8. ↵
   1. Balthasar N,
   2. Coppari R,
   3. McMinn J,
   4. Liu SM,
   5. Lee CE,
   6. Tang V,
   7. Kenny CD,
   8. McGovern RA,
   9. Chua SC Jr.,
   10. Elmquist JK
   11. et al.

   2004 Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 42 983–991.
9. ↵
   1. Bernet F,
   2. Dedieu JF,
   3. Laborie C,
   4. Montel V &
   5. Dupouy JP

   1998 Circulating neuropeptide Y (NPY) and catecholamines in rat under resting and stress conditions. Arguments for extra-adrenal origin of NPY, adrenal and extra-adrenal sources of catecholamines. Neuroscience Letters 250 45–48.doi:10.1016/S0304-3940(98)00454-6.
10. ↵
    1. Blomqvist AG &
    2. Herzog H

    1997 Y-receptor subtypes – how many more? Trends in Neurosciences 20 294–298.doi:10.1016/S0166-2236(96)01057-0.
11. ↵
    1. Boden G,
    2. Chen X,
    3. Mozzoli M &
    4. Ryan I

    1996 Effect of fasting on serum leptin in normal human subjects. Journal of Clinical Endocrinology and Metabolism 81 3419–3423.doi:10.1210/jc.81.9.3419.
12. ↵
    1. Brighton PJ,
    2. Szekeres PG &
    3. Willars GB

    2004 Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacological Reviews 56 231–248.doi:10.1124/pr.56.2.3.
13. ↵
    1. Devane WA,
    2. Hanus L,
    3. Breuer A,
    4. Pertwee RG,
    5. Stevenson LA &
    6. Griffin G

    1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 1946–1949.doi:10.1126/science.1470919.
14. ↵
    1. Ducy P,
    2. Desbois C,
    3. Boyce B,
    4. Pinero G,
    5. Story B,
    6. Dunstan C,
    7. Smith E,
    8. Bonadio J,
    9. Goldstein S,
    10. Gundberg C
    11. et al.

    1996 Increased bone formation in osteocalcin-deficient mice. Nature 382 448–452.doi:10.1038/382448a0.
15. ↵
    1. Ducy P,
    2. Amling M,
    3. Takeda S,
    4. Priemel M,
    5. Schilling AF,
    6. Beil FT,
    7. Shen J,
    8. Vinson C,
    9. Rueger JM &
    10. Karsenty G

    2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 197–207.doi:10.1016/S0092-8674(00)81558-5.
16. ↵
    1. Elefteriou F,
    2. Takeda S,
    3. Liu X,
    4. Armstrong D &
    5. Karsenty G

    2003 Monosodium glutamate-sensitive hypothalamic neurons contribute to the control of bone mass. Endocrinology 144 3842–3847.doi:10.1210/en.2003-0369.
17. ↵
    1. Elefteriou F,
    2. Takeda S,
    3. Ebihara K,
    4. Magre J,
    5. Patano N,
    6. Kim CA,
    7. Ogawa Y,
    8. Liu X,
    9. Ware SM,
    10. Craigen WJ
    11. et al.

    2004 Serum leptin level is a regulator of bone mass. PNAS 101 3258–3263.doi:10.1073/pnas.0308744101.
18. ↵
    1. Elefteriou F,
    2. Ahn JD,
    3. Takeda S,
    4. Starbuck M,
    5. Yang X,
    6. Liu X,
    7. Kondo H,
    8. Richards WG,
    9. Bannon TW,
    10. Noda M
    11. et al.

    2005 Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 514–520.doi:10.1038/nature03398.
19. ↵
    1. Hamrick MW,
    2. Della-Fera MA,
    3. Choi YH,
    4. Pennington C,
    5. Hartzell D &
    6. Baile CA

    2005 Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. Journal of Bone and Mineral Research 20 994–1001.doi:10.1359/JBMR.050103.
20. ↵
    1. Howlett AC,
    2. Barth F,
    3. Bonner TI,
    4. Cabral G,
    5. Casellas P,
    6. Devane WA,
    7. Felder CC,
    8. Herkenham M,
    9. Mackie K,
    10. Martin BR
    11. et al.

    2002 International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 54 161–202.doi:10.1124/pr.54.2.161.
21. ↵
    1. Idris AI,
    2. van 't Hof RJ,
    3. Greig IR,
    4. Ridge SA,
    5. Baker D,
    6. Ross RA &
    7. Ralston SH

    2005 Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine 11 774–779.doi:10.1038/nm1255.
22. ↵
    1. Igwe JC,
    2. Jiang X,
    3. Paic F,
    4. Ma L,
    5. Adams DJ,
    6. Baldock PA,
    7. Pilbeam CC &
    8. Kalajzic I

    2009 Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. Journal of Cellular Biochemistry 108 621–630.doi:10.1002/jcb.22294.
23. ↵
    1. Ishac EJ,
    2. Jiang L,
    3. Lake KD,
    4. Varga K,
    5. Abood ME &
    6. Kunos G

    1996 Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. British Journal of Pharmacology 118 2023–2028.
24. ↵
    1. Iwaniec UT,
    2. Boghossian S,
    3. Lapke PD,
    4. Turner RT &
    5. Kalra SP

    2007 Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides 28 1012–1019.doi:10.1016/j.peptides.2007.02.001.
25. ↵
    1. Karsak M,
    2. Cohen-Solal M,
    3. Freudenberg J,
    4. Ostertag A,
    5. Morieux C,
    6. Kornak U,
    7. Essig J,
    8. Erxlebe E,
    9. Bab I,
    10. Kubisch C
    11. et al.

    2005 Cannabinoid receptor type 2 gene is associated with human osteoporosis. Human Molecular Genetics 14 3389–3396.doi:10.1093/hmg/ddi370.
26. ↵
    1. Kristensen P,
    2. Judge ME,
    3. Thim L,
    4. Ribel U,
    5. Christjansen KN,
    6. Wulff BS,
    7. Clausen JT,
    8. Jensen PB,
    9. Madsen OD,
    10. Vrang N
    11. et al.

    1998 Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393 72–76.doi:10.1038/29993.
27. ↵
    1. Lauzurica N,
    2. Garcia-Garcia L,
    3. Pinto S,
    4. Fuentes JA &
    5. Delgado M

    2010 Changes in NPY and POMC, but not serotonin transporter, following a restricted feeding/repletion protocol in rats. Brain Research 1313 103–112.doi:10.1016/j.brainres.2009.11.075.
28. ↵
    1. Lin S,
    2. Boey D,
    3. Couzens M,
    4. Lee N,
    5. Sainsbury A &
    6. Herzog H

    2005 Compensatory changes in [¹²⁵I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 39 21–28.doi:10.1016/j.npep.2004.10.002.
29. ↵
    1. Lundberg P,
    2. Allison SJ,
    3. Lee NJ,
    4. Baldock PA,
    5. Brouard N,
    6. Rost S,
    7. Enriquez RF,
    8. Sainsbury A,
    9. Lamghari M,
    10. Simmons P
    11. et al.

    2007 Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. Journal of Biological Chemistry 282 19082–19091.doi:10.1074/jbc.M609629200.
30. ↵
    1. Mackie K

    2008 Signaling via CNS cannabinoid receptors. Molecular and Cellular Endocrinology 286 S60–S65.doi:10.1016/j.mce.2008.01.022.
31. ↵
    1. Mechoulam R,
    2. Ben-Shabat S,
    3. Hanus L,
    4. Ligumsky M,
    5. Kaminski NE &
    6. Schatz AR

    1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50 83–90.doi:10.1016/0006-2952(95)00109-D.
32. ↵
    1. Niederhoffer N,
    2. Schmid K &
    3. Szabo B

    2003 The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn-Schmiedeberg's Archives of Pharmacology 367 434–443.doi:10.1007/s00210-003-0755-y.
33. ↵
    1. Ofek O,
    2. Karsak M,
    3. Leclerc N,
    4. Fogel M,
    5. Frenkel B,
    6. Wright K,
    7. Tam J,
    8. Attar-Namdar M,
    9. Kram V,
    10. Shohami E
    11. et al.

    2006 Peripheral cannabinoid receptor, CB2, regulates bone mass. PNAS 103 696–701.doi:10.1073/pnas.0504187103.
34. ↵
    1. Sainsbury A,
    2. Schwarzer C,
    3. Couzens M &
    4. Herzog H

    2002 Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 51 3420–3427.doi:10.2337/diabetes.51.12.3420.
35. ↵
    1. Sato S,
    2. Hanada R,
    3. Kimura A,
    4. Abe T,
    5. Matsumoto T,
    6. Iwasaki M,
    7. Inose H,
    8. Ida T,
    9. Mieda M,
    10. Takeuchi Y
    11. et al.

    2007 Central control of bone remodeling by neuromedin U. Nature Medicine 13 1234–1240.doi:10.1038/nm1640.
36. ↵
    1. Takeda S,
    2. Elefteriou F,
    3. Levasseur R,
    4. Liu X,
    5. Zhao L,
    6. Parker KL,
    7. Armstrong D,
    8. Ducy P &
    9. Karsenty G

    2002 Leptin regulates bone formation via the sympathetic nervous system. Cell 111 305–317.doi:10.1016/S0092-8674(02)01049-8.
37. ↵
    1. Tam J,
    2. Trembovler V,
    3. Di Marzo V,
    4. Petrosino S,
    5. Leo G,
    6. Alexandrovich A,
    7. Regev E,
    8. Casap N,
    9. Shteyer A,
    10. Ledent C
    11. et al.

    2008 The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB Journal 22 285–294.doi:10.1096/fj.06-7957com.
38. ↵
    1. Wolf G

    2008 Energy regulation by the skeleton. Nutrition Reviews 66 229–233.doi:10.1111/j.1753-4887.2008.00027.x.
39. ↵
    1. Yadav VK,
    2. Oury F,
    3. Suda N,
    4. Liu ZW,
    5. Gao XB,
    6. Confavreux C,
    7. Klemenhagen KC,
    8. Tanaka KF,
    9. Gingrich JA,
    10. Guo XE
    11. et al.

    2009 A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138 976–989.doi:10.1016/j.cell.2009.06.051.
40. ↵
    1. Yamada Y,
    2. Ando F &
    3. Shimokata H

    2007 Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. International Journal of Molecular Medicine 19 791–801.